Bortezomib Production Cost Reports

The report provides a detailed analysis essential for establishing a bortezomib production plant. It encompasses all critical aspects necessary for bortezomib production, including the cost of bortezomib production, bortezomib plant cost, bortezomib production costs, and the overall bortezomib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a bortezomib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Bortezomib is a prescription anticancer drug that is mainly used in the treatment of certain types of cancer. It is primarily prescribed for the treatment of multiple myeloma, which is a cancer of plasma cells, and is also used in the treatment of some cases of mantle cell lymphoma. It works by blocking a group of proteins in cells called proteasomes, which helps slow down or stop the growth of cancer cells. It is usually given as an injection under the skin or into a vein and is often combined with other cancer drugs to improve its effectiveness. It is commonly given as part of combination therapy along with other medicines such as corticosteroids and immunomodulatory agents to improve treatment outcomes. It is also used in certain cases of relapsed or refractory blood cancers where earlier treatments have not been effective. In addition, it plays a role in stem cell transplant preparation by helping reduce the number of cancerous cells before the procedure.

The demand for bortezomib is driven by its application as an antineoplastic agent in the treatment of refractory multiple myeloma and certain lymphomas, which boosts its market expansion. Its application as an anticancer drug for the treatment of multiple myeloma and mantle cell lymphoma significantly fuels its demand in the medical and pharmaceutical industries. Its use as an important compound in targeted cancer therapy to help manage disease progression and improve survival rates in patients also promotes its demand in the medical sector. Its demand as an antineoplastic agent in ongoing clinical research to explore its potential use in treating other types of cancers and immune-related disorders further fuels its market growth. Additionally, industrial bortezomib procurement is influenced by several factors, including the availability and cost of main pharmaceutical intermediates, strict regulatory compliance, and quality standards required for injectable cancer medicines. Moreover, advancements in drug production technologies, reliable supplier networks, cold-chain logistics, and the growing focus on sustainable and efficient production processes largely impact its procurement strategies globally.

Raw Material for Bortezomib Production

According to the bortezomib production plant project report, the major raw materials for bortezomib production include protected leucine boronic acid pinanediol ester, N-Boc phenylalanine, and isobutyl boronic acid.

Production Process of Bortezomib

The extensive bortezomib production cost report consists of the following industrial production process:

1. Production via Transesterification: The production process of bortezomib begins with the coupling of a protected leucine boronic acid pinanediol ester with N-Boc phenylalanine using TBTU (coupling reagent) to form the initial dipeptide intermediate. After this step, the Boc protecting group is removed to obtain the free amine derivative. Then, this intermediate is subjected to N-acylation to produce the desired dipeptide boronate ester. Finally, the boronic ester protecting group is deprotected through a biphasic transfer esterification using isobutyl boronic acid, followed by extractive workup to obtain bortezomib as the desired product.

Bortezomib is a dipeptidyl boronic acid derivative that acts as a potent and reversible proteasome inhibitor. It appears as a white-to-off-white crystalline powder that is hygroscopic and sensitive to moisture. The molecular formula of the compound is C19H25BN4O4, and its molar mass is 384.24 g/mol. It has a density of approximately 1.21 g/cm³, and it has a melting point in the range of 122–124 degrees Celsius. The boiling point of the compound is approximately 684.30 degrees Celsius. It is commercially marketed under the brand name Velcade. It is soluble in chloroform, dimethyl sulfoxide (DMSO), ethanol, and methanol, but it is only slightly soluble in water, with an aqueous solubility of approximately 3.3 to 3.8 mg/mL. The compound must be stored at or below −20 degrees Celsius under an inert atmosphere to maintain its stability. It is classified as a hazardous substance and is toxic if swallowed, inhaled, or absorbed through the skin. It is recommended to wear appropriate protective clothing, gloves, and eye protection while handling the compound. Prolonged or repeated exposure may cause serious adverse health effects, including peripheral neuropathy, gastrointestinal disturbances, thrombocytopenia, and neutropenia.